In a phase 3, double-blind, placebo-controlled trial across 22 centres in China, 1089 adults with sepsis were analysed. Mortality at 28 days was 23.4% with thymosin alpha 1 and 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77 to 1.27).
Wu J et al., BMJ 2025 (TESTS)Free shipping over €250 · Tracked, discreet delivery in Europe
premium-grade research peptides
Thymosin Alpha 110 mg
Lyophilized peptide · single vial
What it is
Thymosin alpha 1 is a 28-amino-acid acetylated peptide derived from prothymosin alpha and first isolated from thymic tissue. It is known in clinical literature as thymalfasin and is studied as an immune modulator. Published research covers sepsis, chronic hepatitis B and severe viral respiratory illness.
- Class
- Regenerative Peptides
- Formula
- Thymosin Alpha 1 · 10 mg
- Format
- Lyophilized powder
How it works
Thymosin Alpha-1 is a synthetic 28-amino-acid version of a natural thymic peptide, studied for immune modulation.
Immune
A T-cell maturation signal
Thymosin Alpha-1 promotes the maturation and differentiation of T-cells in immunology research.
TLR
Acts on toll-like receptors
The peptide signals through toll-like receptors on immune cells, a pathway studied for modulating innate immunity.
Modulation
Balance over stimulation
Research frames thymosin alpha-1 as an immune modulator, studied for restoring balance rather than simply stimulating.
Key benefits
- Lyophilized powder, reconstituted for repeatable preparation.
- COA-verified identity and purity, batch by batch.
- Research-use plans built around a compound-specific question.
Laboratory research only. Not for human or veterinary use.
What published research is studying
Human clinical data- 28-day all-cause mortality in adults with sepsis (phase 3 and earlier randomized trials)
- Immune restoration markers such as monocyte HLA-DR and CD4+ and CD8+ T-cell counts in critical illness
- Virological and biochemical response in chronic hepatitis B, compared with interferon alpha
- Outcomes and T-cell exhaustion markers in severe COVID-19 (retrospective cohorts)
Human evidence is substantial but conflicting: a 1106-participant phase 3 trial found no mortality difference in sepsis, while smaller and earlier trials reported benefit.
Key research findings and references
Key research findings
In an earlier multicentre randomized trial of 361 adults with severe sepsis, 28-day mortality was 26.0% versus 35.0% in controls (relative risk 0.74, 95% CI 0.54 to 1.02). Monocyte HLA-DR improved more on days 3 and 7.
Wu J et al., Crit Care 2013 (ETASS)A 2025 systematic review of 11 randomized trials in 1927 patients with sepsis found a pooled 28-day mortality odds ratio of 0.73 (95% CI 0.59 to 0.90). The high-quality and multicentre subgroups showed no significant difference.
Gu B et al., Front Cell Infect Microbiol 2025In a meta-analysis of 4 randomized trials in 199 patients with chronic hepatitis B, complete response favoured thymosin alpha 1 over interferon alpha. That comparison, 6 months after therapy ended, gave an odds ratio of 2.69 (95% CI 1.47 to 4.91).
Yang YF et al., Antiviral Res 2008Published study duration
- Phase 3 sepsis trial: subcutaneous injection every 12 hours for 7 days, with the primary outcome assessed at 28 days (NCT02867267).
- ETASS sepsis trial: 28-day follow-up, with immune markers measured on days 0, 3 and 7 (NCT00711620).
- Chronic hepatitis B trials in the meta-analysis: 6 months of treatment, with response reassessed 6 months after treatment ended (Yang 2008).
Research endpoints
- 28-day all-cause mortality
- Monocyte HLA-DR expression
- Sequential Organ Failure Assessment (SOFA) score
- CD4+ and CD8+ T-cell counts and T-cell exhaustion markers
- Virological, biochemical and complete response rates in hepatitis B
References
- Wu J et al., BMJ 2025. The efficacy and safety of thymosin alpha1 for sepsis (TESTS), phase 3 trial
- ClinicalTrials.gov NCT02867267. The Efficacy and Safety of Ta1 for Sepsis
- Wu J et al., Crit Care 2013. Efficacy of thymosin alpha 1 for severe sepsis (ETASS)
- Gu B et al., Front Cell Infect Microbiol 2025. Efficacy of thymosin alpha1 for sepsis, systematic review and meta-analysis
- Yang YF et al., Antiviral Res 2008. Thymosin alpha-1 versus interferon alpha in chronic hepatitis B, meta-analysis
- Liu Y et al., Clin Infect Dis 2020. Thymosin alpha 1 and mortality in severe COVID-19, retrospective cohort
Summaries of published research, for context only. Research use only. Not for human or veterinary use.
premium-grade research peptides
Thymosin Alpha 110 mg
Choose your vial
Choose strength
Quantity
1 vial
Add 2 more, save 5%
1 × Thymosin Alpha 1 · 10 mg€95 / vial
€95
Free1 × 3 ml bacteriostatic water · 10 × 0.5 ml syringes · 10 × alcohol swabs · uu.life research handling card
- €155 to free shipping
- Ships in 1-2 business days
- Discreet EU
What you get
- 1 × Thymosin Alpha 1 · 10 mg
Medical supply kitFreeOne kit with every vial1 × 3 ml bacteriostatic water10 × 0.5 ml syringes10 × alcohol swabs- uu.life research handling card
One supply kit ships with every vial: the counts above follow the quantity.
Optional spare suppliesHow To Use The Vials
The standard supplies above ship free with every vial. Add extras only if the research plan needs more.
Independently lab tested
99%+ purity standard
Identity verified by LC-MS
Batch COA available
Tracked delivery to European Union
Research bundles
Explore research bundles
Curated pairs and blends this compound is studied alongside. Priced live from the catalogue.
Research pairRecover bundle
BPC-157 + TB-500
The best-known recovery pairing in peptide research. Both compounds are studied for tissue repair, and they are studied together because the mechanisms differ.
Research handling
Full handling guide- 01
Lyophilized, sealed, batch-numbered
Each vial ships as a freeze-dried powder under an inert seal, tied to the batch on its Certificate of Analysis.
- 02
Store cold and dark
Unopened vials are kept refrigerated at 2-8°C away from light. Reconstituted material is stored refrigerated and used within the window the research plan defines.
- 03
Reconstitute with bacteriostatic water
The included bacteriostatic water is added slowly down the vial wall and the vial is swirled, never shaken.
- 04
Research use only
Supplied for laboratory research. Not for human or veterinary use. Handle with the personal protective equipment the laboratory requires.
Before you order
What ships in the box?
The vials selected, plus a free supply kit with every vial: one 3 ml bacteriostatic water, ten 0.5 ml syringes and ten alcohol swabs per vial, and the uu.life research handling card.
How does volume pricing work?
The price per vial depends on how many vials of the same strength are on the line. 3-4 vials take 5% off, 5 or more take 10% off. The discount is applied automatically and shows on the product page, in the cart and at checkout.
Is every batch tested?
Yes. Every batch is tested by an independent laboratory for identity and purity, and the Certificate of Analysis is linked from this page and the lab-testing library.
How fast is delivery?
Orders are typically dispatched within 1-2 business days and arrive across most of Europe in 3-5 business days, tracked, in discreet packaging. Orders over €250 ship free, and Shipping Protection can be added at checkout.
Is this for human use?
No. Every product is sold for laboratory research only and is not for human or veterinary use.
Ready to order Thymosin Alpha 1?
Choose a strength and quantity above. Volume pricing applies automatically.
Quality you can trace.
Batch-tested purity
Every vial ships with a Certificate of Analysis from an independent third-party lab. No exceptions.
Fast shipping
Orders are typically dispatched within 1-2 business days. Most European deliveries arrive in 3-5 business days.
Replacement guarantee
Arrived damaged? Send photos and the order number and a replacement is arranged.
You may also research.
Best seller. Among the most ordered research lines over the last 90 days.Regenerative PeptidesKlowFour peptide blend80 mg€199/ vial1
Popular stack. A multi-peptide blend, one vial instead of several.Regenerative PeptidesWolverineBPC + TB blend€89/ vial1
Most studied. The deepest published literature in its research class.Regenerative PeptidesBPC-157Tendon · gut10 mg€70/ vial1
Regenerative PeptidesSS-31Mitochondrial€69/ vial1